اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,944
تعداد مقالات33,229
تعداد مشاهده مقاله43,862,161
تعداد دریافت فایل اصل مقاله20,368,727
Khalaf, Amal, Sabeeh, Fawaz. (1403). Immunological and cytokine profile (IL-25 and IL-35) in patients with Entamoeba histolytica infection in Southern Iraq. سامانه مدیریت نشریات علمی, 79(2), 315-320. doi: 10.32592/ARI.2024.79.2.315
Amal Khudair Khalaf; Fawaz Abdullah Sabeeh. "Immunological and cytokine profile (IL-25 and IL-35) in patients with Entamoeba histolytica infection in Southern Iraq". سامانه مدیریت نشریات علمی, 79, 2, 1403, 315-320. doi: 10.32592/ARI.2024.79.2.315
Khalaf, Amal, Sabeeh, Fawaz. (1403). 'Immunological and cytokine profile (IL-25 and IL-35) in patients with Entamoeba histolytica infection in Southern Iraq', سامانه مدیریت نشریات علمی, 79(2), pp. 315-320. doi: 10.32592/ARI.2024.79.2.315
Khalaf, Amal, Sabeeh, Fawaz. Immunological and cytokine profile (IL-25 and IL-35) in patients with Entamoeba histolytica infection in Southern Iraq. سامانه مدیریت نشریات علمی, 1403; 79(2): 315-320. doi: 10.32592/ARI.2024.79.2.315

Immunological and cytokine profile (IL-25 and IL-35) in patients with Entamoeba histolytica infection in Southern Iraq

Archives of Razi Institute
مقاله 11، دوره 79، شماره 2، خرداد و تیر 2024، صفحه 315-320    اصل مقاله (496.79 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.32592/ARI.2024.79.2.315
نویسندگان
Amal Khudair Khalaf* 1؛ Fawaz Abdullah Sabeeh2
1Department of Microbiology, College of Medicine, University of Thi-qar, Thi-qar, Iraq.
2Department of Microbiology, College of Medicine, University of Thi-qar, Thi-qar, Iraq
چکیده
Amoebiasis is an intestinal disease caused by a unicellular parasite called Entamoeba histolytica. Interleukin-35 (IL-35) is the most recent specific member in the IL-12 family, that plays a principal role in the inhibitory function of regulatory T cells (Tregs) to restrain inflammatory reactions. IL-25 from the IL-17 family, which is broadly released by Th2 cells and epithelial cells is a warning signal produced during cell or tissue injury for triggering immune cells. The present study was designed to determine the cytokine profile (IL-25 and IL-35) in patients with E. histolytica infection in Southern Iraq. This hospital-based study was carried out from August 2022 to May 2023. The study participants were patients suffering from E. histolytica infection referred to the Infectious Diseases Wards of the general hospitals in Thi-qar Province, Southern Iraq. At first, the E. histolytic amebiasis in patients was approved by the nested multiplex PCR. All collected sera were tested using the Human Interleukin 35 (Biotech, China, Cat.RD-IL35-Hu) and IL25 (Biotech, China, Cat.RD-IL25-Hu) ELISA Kits based on the producer’s instructions. A total of 80 patients including 50 patients with E. histolytica infection and 30 people in control group with no E. histolytica infection were included in the present study. The results showed a significant difference (p<0.001) in the serum level of IL-25 among patients with E. histolytica infection (4275.19 pg/mL) in comparison with people in the control group with no E. histolytica infection (2186 pg/mL). The statistical analysis showed that there is no significant difference in the serum level of IL-35 patients with E. histolytica infection in comparison with people in the control group with no E. histolytica infection. The findings of the present investigation revealed the high levels of IL-25 in patients with E. histolytica infection; indicating the important role of IL-25 in activating the immune system during intestinal inflammation. Therefore, this cytokine can be used as a diagnosis marker for E. histolytica infection.
کلیدواژه‌ها
Amoebiasis؛ cytokine؛ ELISA؛ PCR
سایر فایل های مرتبط با مقاله
مراجع
  1. Stanley SL. Amoebiasis. The lancet. 2003;361(9362):1025-34.
  2. Nasrallah J, Akhoundi M, Haouchine D, Marteau A, Mantelet S, Wind P, Benamouzig R, Bouchaud O, Dhote R, Izri A. Updates on the worldwide burden of amoebiasis: A case series and literature review. Journal of Infection and Public Health. 2022.
  3. Shirley DT, Farr L, Watanabe K, Moonah S. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis. Open Forum Infect Dis. 2018;5(7):ofy161.
  4. Mahmoudvand H, Mohebali M, Sharifi I, Keshavarz H, Hajjaran H, Akhoundi B, Jahanbakhsh S, Zarean M, Javadi A. Epidemiological aspects of visceral leishmaniasis in Baft district, Kerman Province, Southeast of Iran. Iranian journal of parasitology. 2011;6(1):1.
  5. Gupta P, Singh KK, Balodhi A, Jain K, Deeba F, Salam N. Prevalence of amoebiasis and associated complications in India: a systematic review. Acta parasitologica. 2022;67(2):947-61.
  6. Uribe-Querol E, Rosales C. Immune response to the enteric parasite Entamoeba histolytica. Physiology. 2020;35(4):244-60.
  7. Nakada-Tsukui K, Nozaki T. Immune response of amebiasis and immune evasion by Entamoeba histolytica. Frontiers in immunology. 2016;7:175.
  8. Moonah SN, Jiang NM, Petri Jr WA. Host immune response to intestinal amebiasis. PLoS pathogens. 2013;9(8):e1003489.
  9. Ye C, Yano H, Workman CJ, Vignali DA. Interleukin-35: structure, function and its impact on immune-related diseases. Journal of Interferon & Cytokine Research. 2021;41(11):391-406.
  10. Yuan Q, Peng N, Xiao F, Shi X, Zhu B, Rui K, Tian J, Lu L. New insights into the function of Interleukin-25 in disease pathogenesis. Biomarker Research. 2023;11(1):1-6.
  11. Abozahra R, Mokhles M, Baraka K. Prevalence and Molecular Differentiation of Entamoeba histolytica, Entamoeba dispar, Entamoeba moshkovskii, and Entamoeba hartmanni in Egypt. Acta Parasitol. 2020;65(4):929-935.
  12. Al‐Areeqi MA, Sady H, Al‐Mekhlafi HM, Anuar TS, Al‐Adhroey AH, Atroosh WM, Dawaki S, Elyana FN, Nasr NA, Ithoi I, Lau YL. First molecular epidemiology of Entamoeba histolytica, E. dispar and E. moshkovskii infections in Yemen: different species‐specific associated risk factors. Tropical Medicine & International Health. 2017;22(4):493-504.
  13. Haque R, Huston CD, Hughes M, Houpt E, Petri Jr WA. Amebiasis. New England journal of medicine. 2003;348(16):1565-73.
  14. Moonah SN, Jiang NM, Petri Jr WA. Host immune response to intestinal amebiasis. PLoS pathogens. 2013;9(8):e1003489.
  15. Feng YH, Mao H. Expression and preliminary functional analysis of Siglec-F on mouse macrophages. Journal of Zhejiang University SCIENCE B. 2012;13:386-94.
  16. Al-Salehy ZKhA, Mohammad ZAA. Relationship between fecal calprotection and other immunological parameters in diarrheal children infected with Entamoeba histolytica and pathogenic bacteria in Thi-Qar province. Plant Archives, 2020; 20(1): 1089-1095.
  17. Buonomo EL, Cowardin CA, Wilson MG, Saleh MM, Pramoonjago P, Petri WA. Microbiota-regulated IL-25 increases eosinophil number to provide protection during Clostridium difficile infection. Cell reports. 2016;16(2):432-43.
  18. Noor Z, Watanabe K, Abhyankar MM, Burgess SL, Buonomo EL, Cowardin CA, Petri Jr WA. Role of eosinophils and tumor necrosis factor alpha in interleukin-25-mediated protection from amebic colitis. MBio. 2017;8(1):10-128.
 

 

 

 

 

 

 

 

 

 

 

  1. Von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2–epithelial response circuit. Nature. 2016;529(7585):221-5.
  2. Guo X, Barroso L, Lyerly DM, Petri Jr WA, Houpt ER. CD4+ and CD8+ T cell-and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine. Vaccine. 2011;29(4):772-7.
  3. Liu Y, Shao Z, Shangguan G, Bie Q, Zhang B. Biological properties and the role of IL-25 in disease pathogenesis. Journal of Immunology Research. 2018.
  4. Camelo A, Barlow JL, Drynan LF, Neill DR, Ballantyne SJ, Wong SH, Pannell R, Gao W, Wrigley K, Sprenkle J, McKenzie AN. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. Journal of gastroenterology. 2012;47:1198-211.
  5. Cao Q, Yu D, Georgescu M, Han Z, Wu J. Impacts of land use and land cover change on regional climate: A case study in the agro-pastoral transitional zone of China. Environmental Research Letters. 2015;10(12):124025.
  6. Du WX, He Y, Jiang HY, Ai Q, Yu JL. Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates. Clinica Chimica Acta. 2016;462:90-5.
  7. Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine. 2015;75(2):389-402.
  8. Banchereau J, Pascual V, O'garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nature immunology. 2012;13(10):925-31.
  9. Choi J, Leung PS, Bowlus C, Gershwin ME. IL-35 and autoimmunity: a comprehensive perspective. Clinical reviews in allergy & immunology. 2015;49:327-32.
  10. Dong J, Wong CK, Cai Z, Jiao D, Chu M, Lam CW. Amelioration of allergic airway inflammation in mice by regulatory IL‐35 through dampening inflammatory dendritic cells. Allergy. 2015;70(8):921-32.
آمار
تعداد مشاهده مقاله: 12,286
تعداد دریافت فایل اصل مقاله: 462


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب